Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

New Data Presented at the Meeting Demonstrate Vitamin E May Help Prevent

Cardiovascular Events in Hp2-2 Diabetes

MONTVALE, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced new data demonstrating that discontinuation of Vitamin E in patients with the Hp2-2 Diabetes may result in an increased risk of heart attack and rapid deterioration of HDL function. These results were presented today at the Annual Scientific Sessions of the American Heart Association, underway in New Orleans.

"These data demonstrate that after detecting Hp2-2 Diabetes, physicians modified treatment and achieved improved outcomes for specific patients by prescribing vitamin E. These benefits were lost when treatment with vitamin E was abandoned," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "These types of studies provide confirmation that our clinical laboratory test which determines haptoglobin genotype may be useful in selecting and guiding patient therapy. We believe that the use of our test will be an important facilitator of personalized medicine and will provide a standard by which physicians can influence clinical outcome."

About the Study

In a prospective study called ICARE, 2,241 individuals with diabetes mellitus age 55 or over from 47 primary-care clinics in Israel underwent haptoglobin genotype testing and were randomized to receive either Vitamin E or placebo. The subjects were then followed for three years to track heart attack (myocardial infarction or MI), stroke and death (cardiovascular and all cause). During the study, it was determined that those who had the Hp2-2 genotype and who also received vitamin E had a significantly lower incidence of MI
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Fayetteville, Arkansas (PRWEB) November 20, 2014 ... partners, Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, ... equipment, announced that they have been selected to ... City of Fayetteville, Arkansas Paul R. Noland Wastewater ... feature BlueInGreen’s patented HyDOZ® gas dissolution ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industry” is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... enrolment in a clinical trial using intravenous ... chemotherapeutic agent,as well as immune modulator, in ... Dr. James Spicer of King,s College in ...
... The International Center for Adult,Stem Cell Education ... officially launched a global communications and government-political,affairs ... Injury Symposium,Olfactory Mucosa Autografts (OMA) and Rehabilitation ... 10th in Argostolli, Kefalonia, Greece. The ICASCE ...
... May 9 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin Board: ... in the manufacture, research, development,marketing and distribution of ... for its new plant at Qing Pu, Shanghai., ... MT capacity is the cornerstone of our,growth strategy. ...
Cached Biology Technology:Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial 3International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 2China-Biotics, Inc. Completes Foundation for Its New Plant 2
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... HILTON HEAD, SCThe coordination of two systems are key for ... The first are the lower limbs, which allow the animal ... a complicated respiratory system, which allows a horse to take ... For more than a decade a team of researchers has ...
... Calorie restriction, a diet that is low in calories ... extending life in people as it is in rodents, according ... Louis. Previous research had shown that laboratory animals ... up to 50 percent longer. Because of those findings, some ...
... - The economic impact of climate change will cost ... delaying action will raise the price tag, concludes the ... Maryland,s Center for Integrative Environmental Research (CIER). The ... effects on North Carolina, North Dakota, Pennsylvania and Tennessee. ...
Cached Biology News:Galloping and breathing at high speed 2Galloping and breathing at high speed 3Researchers note differences between people and animals on calorie restriction 2Researchers note differences between people and animals on calorie restriction 3Severe climate change costs forecast for Pennsylvania, N.C., Tennessee, N.D. 2Severe climate change costs forecast for Pennsylvania, N.C., Tennessee, N.D. 3Severe climate change costs forecast for Pennsylvania, N.C., Tennessee, N.D. 4
... us with target blotted protein on PVDF ... in water), The N-terminal sequence of proteins ... samples purified by HPLC or mono-and bidimensional ... difluoride) membranes using the well known EDMAN ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
... product contains 5 ml Dynabeads® ... the monoclonal BerEP4 against the ... cell adhesion molecule). Also available ... 2 x 10e7 MNC in ...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: